公开(公告)号：US10688180B2

公开(公告)日：2020-06-23

申请号：US15703126

申请日：2017-09-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Innate Pharma

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: C07K16/00 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

公开(公告)号：US09789182B2

公开(公告)日：2017-10-17

申请号：US14437029

申请日：2013-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  Innate Pharma

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

公开(公告)号：US20150290316A1

公开(公告)日：2015-10-15

申请号：US14432376

申请日：2013-10-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton

IPC: A61K39/395 ,  A61K9/00 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565

Abstract: Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.

Abstract translation: 提供使用抗-KIR抗体与抗PD-1抗体组合的临床治疗癌症的方法（例如，晚期难治性实体瘤或血液恶性肿瘤）。

公开(公告)号：US20150283234A1

公开(公告)日：2015-10-08

申请号：US14437029

申请日：2013-10-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY ,  INNATE PHARMA

Inventor： Robert F. Graziano ,  Ashok K. Gupta ,  Su Young Kim ,  Jon Wigginton ,  Pascale Andre

IPC: A61K39/395 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Abstract translation: 提供了使用抗-KIR抗体与抗CTLA-4抗体组合的临床治疗癌症（例如实体瘤或血液恶性肿瘤）的方法。